-
公开(公告)号:US11572541B2
公开(公告)日:2023-02-07
申请号:US16616932
申请日:2018-05-04
发明人: Andrew D. Weinberg , Ryan Montier , Thomas Duhen , Rebekka Duhen
IPC分类号: C12N5/0783 , A61K35/17 , C07K14/725 , A61K48/00 , C12N15/10 , C12N15/85
摘要: Methods are disclosed for treating a subject with a tumor. These methods include administering to the subject a therapeutically effective amount of CD8+CD39+CD103+ T cells. Methods also are disclosed for isolating a nucleic acid encoding a T cell receptor (TCR) that specifically binds a tumor cell antigen. These methods include isolating CD8+CD39+CD103+ T cells from a sample from a subject with a tumor expressing the tumor cell antigen, and cloning a nucleic acid molecule encoding a TCR from the CD8+CD39+CD103+ T cells. In addition, methods are disclosed for expanding CD8+CD39+CD103+ T cells. In additional embodiments, methods are disclosed for determining if a subject with a tumor will respond to a checkpoint inhibitor. The methods include detecting the presence of CD8+CD39+CD103+ T cells in a biological sample from a subject.
-
公开(公告)号:US20240277842A1
公开(公告)日:2024-08-22
申请号:US18567712
申请日:2022-06-06
申请人: Andrew D. WEINBERG , Thomas DUHEN , Rebekka DUHEN , Jacob MOSES , Providence Health & Services - Oregon , AgonOx, Inc.
发明人: Andrew D. Weinberg , Thomas Duhen , Rebekka Duhen , Jacob Moses
IPC分类号: A61K39/00 , A61K35/17 , A61K45/06 , C07K14/725 , C12N5/0783
CPC分类号: A61K39/4611 , A61K35/17 , A61K39/464499 , A61K45/06 , C07K14/7051 , C12N5/0636 , C12N2501/2302
摘要: Methods are disclosed for treating a subject with a tumor. These methods include administering to the subject a therapeutically effective amount of CD4+ICOS+PD-1+CXCR5+ T cells. Methods also are disclosed for isolating a nucleic acid encoding a T cell receptor (TCR) that specifically binds a tumor cell antigen. These methods include isolating CD4+ICOS+PD-1+CXCR5+ T cells from a sample from a subject with a tumor expressing the tumor cell antigen, and cloning a nucleic acid molecule encoding a TCR from the CD4+ICOS+PD-1+CXCR5+ T cells. In addition, methods are disclosed for expanding CD4+ICOS+PD-1+CXCR5+ T cells. In additional embodiments, methods are disclosed for determining if a subject with a tumor will respond to a checkpoint inhibitor. The methods include detecting the presence of CD4+ICOS+PD-1+CXCR5+ T cells in a biological sample from a subject. Compositions of use in these methods are also disclosed.
-
3.
公开(公告)号:US20230220340A1
公开(公告)日:2023-07-13
申请号:US18147981
申请日:2022-12-29
发明人: Andrew D. Weinberg , Ryan Montler , Thomas Duhen , Rebekka Duhen
IPC分类号: C12N5/0783 , A61K35/17 , C07K14/725 , C12N15/10 , C12N15/85 , A61K48/00
CPC分类号: C12N5/0636 , A61K35/17 , C07K14/7051 , C12N15/1003 , C12N15/85 , C12N2501/2315 , C12N2502/00 , C12N2500/32 , A61K48/00
摘要: Methods are disclosed for treating a subject with a tumor. These methods include administering to the subject a therapeutically effective amount of CD8+CD39+CD103+ T cells. Methods also are disclosed for isolating a nucleic acid encoding a T cell receptor (TCR) that specifically binds a tumor cell antigen. These methods include isolating CD8+CD39+CD103+ T cells from a sample from a subject with a tumor expressing the tumor cell antigen, and cloning a nucleic acid molecule encoding a TCR from the CD8+CD39+CD103+ T cells. In addition, methods are disclosed for expanding CD8+CD39+CD103+ T cells. In additional embodiments, methods are disclosed for determining if a subject with a tumor will respond to a checkpoint inhibitor. The methods include detecting the presence of CD8+CD39+CD103+ T cells in a biological sample from a subject.
-
4.
公开(公告)号:US20200149008A1
公开(公告)日:2020-05-14
申请号:US16616932
申请日:2018-05-04
发明人: Andrew D. Weinberg , Ryan Montler , Thomas Duhen , Rebekka Duhen
IPC分类号: C12N5/0783 , C12N15/10 , C07K14/725 , C12N15/85 , A61K35/17
摘要: Methods are disclosed for treating a subject with a tumor. These methods include administering to the subject a therapeutically effective amount of CD8+CD39+CD103+ T cells. Methods also are disclosed for isolating a nucleic acid encoding a T cell receptor (TCR) that specifically binds a tumor cell antigen. These methods include isolating CD8+CD39+CD103+ T cells from a sample from a subject with a tumor expressing the tumor cell antigen, and cloning a nucleic acid molecule encoding a TCR from the CD8+CD39+CD103+ T cells. In addition, methods are disclosed for expanding CD8+CD39+CD103+ T cells. In additional embodiments, methods are disclosed for determining if a subject with a tumor will respond to a checkpoint inhibitor. The methods include detecting the presence of CD8+CD39+CD103+ T cells in a biological sample from a subject.
-
-
-